{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:40:06Z","timestamp":1792773606107,"version":"4.5.0"},"reference-count":79,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Heart failure (HF) remains a major cause of morbidity, mortality, and increased healthcare costs worldwide, and is recognized as the result of progressive cardiovascular\u2013kidney\u2013metabolic (CKM) syndrome. Obesity, type 2 diabetes, chronic kidney disease, hypertension, and atherosclerotic cardiovascular disease frequently coexist and interact through shared pathophysiological mechanisms that promote HF onset, especially with preserved ejection fraction (HFpEF). This European Journal of Heart Failure (EJHF) Expert Consensus Statement synthesizes contemporary evidence supporting pharmacological strategies to prevent HF across the CKM spectrum. Foundational therapies, including renin\u2013angiotensin system inhibitors, sodium\u2013glucose cotransporter 2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and incretin-based agents, demonstrate complementary benefits in reducing HF events, cardiovascular death, and chronic kidney disease (CKD) progression in high-risk populations. Early, parallel initiation of these therapies may modify disease trajectory and attenuate progression from at-risk and pre-HF stages to overt clinical HF. This document further emphasizes the need for an up-front, accelerated implementation strategy supported by structured monitoring, multidisciplinary CKM care pathways, and proactive management of laboratory abnormalities. Overcoming barriers such as clinical inertia, safety misperceptions, polypharmacy, cost constraints, and inequities in access is essential to translate evidence into population-level impact. Harmonization of prevention frameworks across cardiology, nephrology, endocrinology, and primary care societies is urgently required. Integrated, cross-disciplinary implementation of evidence-based CKM management offers a realistic opportunity to reduce incident HF and mitigate its growing global burden.<\/jats:p>","DOI":"10.1093\/ejhf\/xuag301","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:56:57Z","timestamp":1790769417000},"source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological treatment strategies to prevent heart failure across the cardiovascular-kidney-metabolic spectrum: an EJHF Expert Consensus Statement"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4846-8529","authenticated-orcid":false,"given":"Riccardo M","family":"Inciardi","sequence":"first","affiliation":[{"name":"Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , P.zle Spedali Civili, 1 Brescia 25123 ,","place":["Italy"]},{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , S\u00f6dersjukhuset, Sjukhusbacken 10, SE-118 83 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Abdin","sequence":"additional","affiliation":[{"name":"Internal Medicine Clinic III, Cardiology, Angiology and Intensive Care Medicine, Saarland University Hospital , Homburg\/Saar ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6701-7072","authenticated-orcid":false,"given":"Magdy","family":"Abdelhamid","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Kasr Al Ainy, Cardiology Department, Cairo University , Giza ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ambrosio","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Universita Degli Studi di Perugia , Perugia ,","place":["Italy"]},{"name":"Italian National Institute for Cardiovascular Research\u2014INRC , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2976-2514","authenticated-orcid":false,"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Internal Medicine Clinic III, Cardiology, Angiology and Intensive Care Medicine, Saarland University Hospital , Homburg\/Saar ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7609-6297","authenticated-orcid":false,"given":"Antonio","family":"Cannata","sequence":"additional","affiliation":[{"name":"School of Cardiovascular Medicine and Sciences, King's College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3197-3628","authenticated-orcid":false,"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[{"name":"Emergency Institute for Cardiovascular Diseases \u201cProf Dr CC Iliescu\u201d , Bucharest ,","place":["Romania"]},{"name":"Department of Medicine, Carol Davila University of Medicine and Pharmacy , Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6967-5685","authenticated-orcid":false,"given":"Francesco","family":"Cosentino","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Esteban-Fernandez","sequence":"additional","affiliation":[{"name":"Cardiology Service, Hospital Universitario Severo Ochoa , Madrid ,","place":["Spain"]},{"name":"Facultad de Ciencias Biom\u00e9dicas y de la Salud, Universidad Alfonso X el Sabio (UAX) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elsanhoury","sequence":"additional","affiliation":[{"name":"Berlin Institute of Health (BIH), Center for Regenerative Therapies (BCRT), Charit\u00e9-University Medicine Berlin , Berlin 13353 ,","place":["Germany"]},{"name":"DZHK (German Centre for Cardiovascular Research), Partner Ssite Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[{"name":"CHRU de Nancy, Universit\u00e9 de Lorraine, Centre Dd'Investigation Clinique Plurith\u00e9matique 1433, INSERM U1116\u2014DCAC, and F-CRIN iINI-CRCT, Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-9877","authenticated-orcid":false,"given":"Felix","family":"Lindberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , S\u00f6dersjukhuset, Sjukhusbacken 10, SE-118 83 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Van Linthout","sequence":"additional","affiliation":[{"name":"DZHK (German Centre for Cardiovascular Research), Partner Ssite Berlin , Berlin ,","place":["Germany"]},{"name":"Deutsches Herzzentrum der Charit\u00e9 (DHZC), Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow-Klinikum , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo M","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , P.zle Spedali Civili, 1 Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9276-8380","authenticated-orcid":false,"given":"Brendon L","family":"Neuen","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W","family":"Ostrominski","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4538-6811","authenticated-orcid":false,"given":"Davide","family":"Stolfo","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , S\u00f6dersjukhuset, Sjukhusbacken 10, SE-118 83 Stockholm ,","place":["Sweden"]},{"name":"Cardiothoracic Department, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) and University Hospital of Udine , Udine ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-1953","authenticated-orcid":false,"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-9597","authenticated-orcid":false,"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Mullens","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ziekenhuis Oost-Limburg , Genk ,","place":["Belgium"]},{"name":"Department of Medicine, Hasselt University , Hasselt ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6691-8568","authenticated-orcid":false,"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology, Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital , Milan ,","place":["Italy"]},{"name":"Cardiology, IRCCS San Raffaele Scientific Institute , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7732-0887","authenticated-orcid":false,"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , S\u00f6dersjukhuset, Sjukhusbacken 10, SE-118 83 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026102311414776300_xuag301-B1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026102311414776300_xuag301-B2","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(25)01384-4","article-title":"Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention","volume":"406","author":"Ostrominski","year":"2025","journal-title":"Lancet"},{"key":"2026102311414776300_xuag301-B3","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"2026102311414776300_xuag301-B4","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1161\/CIR.0000000000001453","article-title":"2026 AHA\/ACC\/ADA\/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"154","author":"Ndumele","year":"2026","journal-title":"Circulation"},{"key":"2026102311414776300_xuag301-B5","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.jacc.2025.12.029","article-title":"Heart failure prevention: evidence generation, trial design, and regulatory pathways","volume":"87","author":"Butler","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"2026102311414776300_xuag301-B6","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026102311414776300_xuag301-B7","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026102311414776300_xuag301-B8","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"2026102311414776300_xuag301-B9","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/eurheartj\/ehae775","article-title":"From cardiorenal to cardiovascular-kidney-metabolic syndromes","volume":"46","author":"Braunwald","year":"2025","journal-title":"Eur Heart J"},{"key":"2026102311414776300_xuag301-B10","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1681\/ASN.0000000658","article-title":"Global burden of the key components of cardiovascular-kidney-metabolic syndrome","volume":"36","author":"Xie","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"2026102311414776300_xuag301-B11","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.jacc.2024.03.368","article-title":"Prevalence of the cardiovascular-kidney-metabolic syndrome in the United States","volume":"83","author":"Minhas","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026102311414776300_xuag301-B12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2025.05.030","article-title":"Rising prevalence of cardiovascular-kidney-metabolic syndrome in China, 2010-2019: National Cross-Sectional Surveys","volume":"86","author":"He","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026102311414776300_xuag301-B13","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf514","article-title":"Cardiovascular-kidney-metabolic syndrome and mortality in a prospective UK cohort study","author":"Mayne","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026102311414776300_xuag301-B14","author":"WHO"},{"key":"2026102311414776300_xuag301-B15","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","article-title":"Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"GBD 2023 Chronic Kidney Disease Collaborators","year":"2025","journal-title":"Lancet"},{"key":"2026102311414776300_xuag301-B16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","author":"Collaborators GAB","year":"2025","journal-title":"Lancet"},{"key":"2026102311414776300_xuag301-B17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.007216","article-title":"Progression of preclinical heart failure: a description of stage A and B heart failure in a community population","volume":"14","author":"Young","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026102311414776300_xuag301-B18","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.jchf.2023.07.001","article-title":"Pre-heart failure: an important opportunity to prevent a deadly disease","volume":"11","author":"Bozkurt","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026102311414776300_xuag301-B19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/ejhf.2351","article-title":"Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology","volume":"24","author":"Piepoli","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026102311414776300_xuag301-B20","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.jacc.2025.07.052","article-title":"Is type 2 diabetes a modifiable risk factor for the evolution and progression of heart failure with a preserved ejection fraction?","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026102311414776300_xuag301-B21","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"2026102311414776300_xuag301-B22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/ehf2.14560","article-title":"Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists","volume":"11","author":"Cimino","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026102311414776300_xuag301-B23","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s11897-023-00613-1","article-title":"Non-alcoholic fatty liver disease as an emerging risk factor for heart failure","volume":"20","author":"Inciardi","year":"2023","journal-title":"Curr Heart Fail Rep"},{"key":"2026102311414776300_xuag301-B24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022308","article-title":"Cardiac structure and function and diabetes-related risk of death or heart failure in older adults","volume":"11","author":"Inciardi","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026102311414776300_xuag301-B25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","article-title":"The transition from hypertension to heart failure: contemporary update","volume":"5","author":"Messerli","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026102311414776300_xuag301-B26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"2026102311414776300_xuag301-B27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12933-025-02753-1","article-title":"Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in older adults with type 2 diabetes mellitus: a target trial emulation study","volume":"24","author":"Zeng","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"2026102311414776300_xuag301-B28","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026102311414776300_xuag301-B29","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102311414776300_xuag301-B30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2026102311414776300_xuag301-B31","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"2026102311414776300_xuag301-B32","doi-asserted-by":"publisher","first-page":"846","DOI":"10.2337\/dc25-0241","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026102311414776300_xuag301-B33","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026102311414776300_xuag301-B34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102311414776300_xuag301-B35","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"2026102311414776300_xuag301-B36","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102311414776300_xuag301-B37","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1016\/S0140-6736(26)01009-3","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)","volume":"407","author":"Neuen","year":"2026","journal-title":"Lancet"},{"key":"2026102311414776300_xuag301-B38","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102311414776300_xuag301-B39","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/aje\/kwae137","article-title":"Cardiorenal effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among people underrepresented in trials: analysis of routinely collected data with emulation of a reference trial (ONTARGET)","volume":"193","author":"Baptiste","year":"2024","journal-title":"Am J Epidemiol"},{"key":"2026102311414776300_xuag301-B40","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jacc.2011.09.040","article-title":"Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial)","volume":"59","author":"Redon","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026102311414776300_xuag301-B41","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"},{"key":"2026102311414776300_xuag301-B42","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1161\/CIRCULATIONAHA.123.068524","article-title":"Accelerated risk-based implementation of guideline-directed medical therapy for type 2 diabetes and chronic kidney disease","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"2026102311414776300_xuag301-B43","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"2026102311414776300_xuag301-B44","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"Cheng","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2026102311414776300_xuag301-B45","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.xkme.2020.04.002","article-title":"Renin-angiotensin system blockade in advanced kidney disease: stop or continue?","volume":"2","author":"Burnier","year":"2020","journal-title":"Kidney Med"},{"key":"2026102311414776300_xuag301-B46","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1093\/ehjcvp\/pvaf055","article-title":"Interdisciplinary recommendations for recurrent hyperkalaemia: insights from The GUARDIAN-HK European Steering Committee","volume":"11","author":"Savarese","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026102311414776300_xuag301-B47","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.029565","article-title":"Updates for cardio-kidney protective effects by angiotensin receptor-neprilysin inhibitor: requirement for additional evidence of kidney protection","volume":"12","author":"Tsukamoto","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026102311414776300_xuag301-B48","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes Mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"2026102311414776300_xuag301-B49","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/ejhf.3558","article-title":"Tailoring medical therapy for heart failure with preserved ejection fraction","volume":"27","author":"Inciardi","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026102311414776300_xuag301-B50","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","article-title":"Effect of SGLT2 inhibitors on cardiovascular outcomes across Various patient populations","volume":"81","author":"Usman","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026102311414776300_xuag301-B51","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium","year":"2022","journal-title":"Lancet"},{"key":"2026102311414776300_xuag301-B52","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR Substudy","volume":"85","author":"Kramer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026102311414776300_xuag301-B53","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/jamainternmed.2025.7774","article-title":"Oral semaglutide and heart failure outcomes in persons with type 2 diabetes: a secondary analysis of the SOUL Randomized Clinical Trial","volume":"186","author":"Pop-Busui","year":"2026","journal-title":"JAMA Intern Med"},{"key":"2026102311414776300_xuag301-B54","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"2026102311414776300_xuag301-B55","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial","volume":"31","author":"Apperloo","year":"2025","journal-title":"Nat Med"},{"key":"2026102311414776300_xuag301-B56","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1161\/CIRCULATIONAHA.124.072889","article-title":"The association between tirzepatide versus insulin glargine and NT-proBNP levels in people with type 2 diabetes with or at elevated risk for cardiovascular disease: post hoc analyses of SURPASS 4","volume":"151","author":"Sattar","year":"2025","journal-title":"Circulation"},{"key":"2026102311414776300_xuag301-B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102637","article-title":"Nonsteroidal and steroidal mineralocorticoid antagonists: rationale, evidence, and unanswered questions","volume":"13","author":"Harrington","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026102311414776300_xuag301-B58","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2026102311414776300_xuag301-B59","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102311414776300_xuag301-B60","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102311414776300_xuag301-B61","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2604625","article-title":"Finerenone in persons with chronic kidney disease without diabetes","volume":"395","author":"Heerspink","year":"2026","journal-title":"N Engl J Med"},{"key":"2026102311414776300_xuag301-B62","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"key":"2026102311414776300_xuag301-B63","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102311414776300_xuag301-B64","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.cardfail.2025.06.013","article-title":"The Continuum of prevention and heart failure in cardiovascular medicine: A Joint Scientific Statement from the Heart Failure Society of America and The American Society for Preventive Cardiology","volume":"32","author":"Lala","year":"2026","journal-title":"J Card Fail"},{"key":"2026102311414776300_xuag301-B65","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"2026102311414776300_xuag301-B66","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jacc.2024.05.057","article-title":"Prescription patterns for sodium-glucose cotransporter 2 inhibitors in U.S. Health systems","volume":"84","author":"Shin","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026102311414776300_xuag301-B67","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/ejhf.3260","article-title":"OPTImal PHARMacological therapy for patients with heart failure: rationale and design of the OPTIPHARM-HF registry","volume":"26","author":"Inciardi","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026102311414776300_xuag301-B68","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1002\/ejhf.70074","article-title":"Contemporary medical therapy for heart failure across the ejection fraction spectrum: the OPTIPHARM-HF registry","volume":"27","author":"Inciardi","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026102311414776300_xuag301-B69","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/ejhf.3214","article-title":"Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice","volume":"26","author":"Savarese","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026102311414776300_xuag301-B70","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/ejhf.3444","article-title":"Translating the 2021 ESC heart failure guideline recommendations in daily practice: results from a heart failure survey. A scientific statement of the ESC Council for Cardiology Practice and the Heart Failure Association of the ESC","volume":"27","author":"Christodorescu","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026102311414776300_xuag301-B71","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/ejhf.3642","article-title":"How to handle polypharmacy in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC","volume":"27","author":"Stolfo","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026102311414776300_xuag301-B72","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012514","article-title":"Natural language processing to adjudicate heart failure hospitalizations in global clinical trials","volume":"18","author":"Marti-Castellote","year":"2025","journal-title":"Circ Heart Fail"},{"key":"2026102311414776300_xuag301-B73","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1056\/NEJMra1510061","article-title":"Adaptive designs for clinical trials","volume":"375","author":"Bhatt","year":"2016","journal-title":"N Engl J Med"},{"key":"2026102311414776300_xuag301-B74","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1002\/ehf2.13462","article-title":"The prognostic value of serial troponin measurements in patients admitted for COVID-19","volume":"8","author":"Nuzzi","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026102311414776300_xuag301-B75","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s00125-018-4642-y","article-title":"Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised steno-2 study","volume":"61","author":"Oellgaard","year":"2018","journal-title":"Diabetologia"},{"key":"2026102311414776300_xuag301-B76","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1093\/eurheartj\/ehag154","article-title":"Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model","volume":"47","author":"SCORE2 Writing Group, European Society of Cardiology\u2019s Cardiovascular Risk Collaboration (CRC) Unit","year":"2026","journal-title":"Eur Heart J"},{"key":"2026102311414776300_xuag301-B77","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jchf.2022.12.005","article-title":"Reclassification of Pre-heart failure stages using cardiac biomarkers: The ARIC Study","volume":"11","author":"Jia","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026102311414776300_xuag301-B78","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide\u2013based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"key":"2026102311414776300_xuag301-B79","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","article-title":"PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial","volume":"62","author":"Huelsmann","year":"2013","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag301\/71547820\/xuag301.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag301\/71547820\/xuag301.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:41:53Z","timestamp":1792770113000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article\/doi\/10.1093\/ejhf\/xuag301\/8857693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":79,"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag301","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"xuag301"}}